No Data
ASCLETIS-B (01672.HK) spent 1.512 million HKD to repurchase 0.5 million shares on December 30.
On December 30, Gelonghui reported that ASCLETIS-B (01672.HK) announced the repurchase of 0.5 million shares at a cost of 1.512 million Hong Kong dollars.
ASCLETIS-B (01672) repurchased approximately 1.4813 million Hong Kong dollars to acquire 0.5 million shares on December 27.
ASCLETIS-B (01672) announced the repurchase on December 27, 2024, costing approximately 1.4813 million Hong Kong dollars...
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
On December 20, ASCLETIS-B (01672.HK) spent 0.073 million Hong Kong dollars to repurchase 0.029 million shares.
On December 20, Gelonghui reported that ASCLETIS-B (01672.HK) announced the repurchase of 0.029 million shares at a cost of 0.073 million HKD on December 20, 2024.
[Brokerage Focus] Founder Securities maintains a recommendation rating for Gilead Sciences (01672). ASC47 combined with semaglutide shows better results in weight loss and muscle preservation compared to monotherapy.
Jinwu Financial News | Founder Securities Research pointed out that Gery Pharmaceutical (01672) recently announced preclinical weight loss data for the obesity treatment candidate drug ASC47 combined with semaglutide. The firm indicated that ASC47 combined with semaglutide outperformed semaglutide alone in both weight loss and total muscle mass in preclinical results: in terms of weight loss, low-dose medication 1 (ASC47, 3mg/kg, subcutaneous injection, once every four weeks) combined with semaglutide, 30nmol/kg, subcutaneous injection, once daily, showed superior results compared to semaglutide alone (30nmol/kg, subcutaneous injection).
Hong Kong stocks volatility | ASCLETIS-B (01672) rose over 13%. The candidate drug ASC47 for treating obesity shows encouraging efficacy in research.
ASCLETIS-B (01672) rose over 13%, as of the time of writing, it increased by 13.01%, trading at 2.78 Hong Kong dollars, with a transaction amount of 3.1806 million Hong Kong dollars.
